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Abstract.  13 
 14 
Sarcosine, a potential biomarker for prostate cancer, can be detected in a solid state enzyme 15 
based biosensor using sarcosine oxidase, with particle immobilised reagents.  A novel fusion 16 
protein of the fluorescent protein, mCherry, sarcosine oxidase (SOx), and the polypeptide R5 17 
(R52-mCherry-SOx-R5-6H), was explored, which allowed self-immobilization on silica 18 
microparticles and long-term (90 days +) retention of activity, even at room temperature. In 19 
contrast, commercial wildtype SOx lost activity in a few days.  A silica-R52-mCherry-SOx-R5-20 
6H microparticle sensor for determination of sarcosine in urine, linked the SOx coproduct, 21 
H2O2, to a measurement catalysed by horseradish peroxidase (HRP) immobilised on silica, in 22 
the presence of Amplex Ultrared (AR) to generate fluorescence at 582 nm. Silica microparticles 23 
carrying all the reagents (R52-mCherry-SOx-R5-6H, HRP and AR) were used to produce a 24 
silica-microparticle biosensor which responded to sarcosine at micromolar levels. Interference 25 
by amino acids and uric acid was examined and it was found that the silica-reagent carrying 26 
system could be calibrated in urine and responded across the clinically relevant concentration 27 
range. This contrasted with similar assays using commercial SOx, where interference inhibited 28 
the sarcosine signal measurement in urine. The microparticle biosensor was tested in urine from 29 
healthy volunteers and prostate cancer patients, showing higher concentrations of sarcosine in 30 
cancer patients consistent with previous reports of elevated sarcosine levels.  31 
 32 
Keywords Silaffins, Enzyme immobilization, Biosensor, Sarcosine, Prostatic carcinoma, urine 33 
 34 
1. Introduction 35 
 36 
Development of in vitro diagnostics (IVDs) to guide earlier diagnosis and more effective 37 
clinical intervention with improved cost effectiveness has become a clear objective in sensor 38 
research [1].  Cancer is not yet well represented in IVD diagnostics, but the need for early 39 
detection and triage is undisputed. It has been noted by Soper et al. [2] that point of care 40 
diagnostics for cancer have been slow to evolve for a variety of reasons. In some cancers this is 41 
partly due to the lack of known robust biomarkers that could act as targets in a diagnostic. In 42 
other cancers, some progress could be made with the production of the right reagents for 43 
identified biomarkers. 44 
 45 
Prostate cancer, for example, is one of the leading causes of cancer death among men [3]. 46 
Although widely used in connection with cancer, detection of elevated levels of prostate-47 
specific antigen (PSA) will identify prostate disease, but not necessarily prostate cancer.  When 48 
the test was first introduced in 1986, it was intended as a marker of disease progression, in 49 
already diagnosed patients, not for cancer diagnosis, but its wider use [4] and the resulting 50 
ambiguity in the result is now driving the search for better biomarkers and thence IVDs [5-7]. 51 
Thus, biopsy and digital rectal examination (DRE) are still the best first approach [8] in 52 
combination with PSA testing. Centralised laboratory testing further supports diagnosis with, 53 
for example, transrectal ultrasound [9] guiding biopsies [10] and an increasing use of magnetic 54 
resonance [11] and positron emission tomography [12].  55 
 56 
PSA is typically measured in blood or serum (recently a study in saliva has also been reported 57 
[13]), but to add value to the PSA test, urine based biomarkers are of special interest, that can 58 
be ‘co-detected’ without invasive sampling, as described by Cao et al [7]. Molecular biomarkers 59 
(metabolite, gene and protein based) are being identified that collectively may lead to better 60 
diagnostics [14, 15] and, in this context, the amino acid, sarcosine (N-methylglycine) has been 61 
studied in both blood and in urine as a marker of early-stage prostate cancer [16]. Although the 62 
measurements in blood have been reported as unremarkable, significantly elevated levels in 63 
urine have been recorded in some studies, for patients with prostate cancer. Furthermore, in a 64 
recent study cancer sniffer dogs were able to distinguish artificial urine samples that had been 65 
doped with sarcosine, with 90% success rate [17]. The possible role of sarcosine is however still 66 
strongly debated [18], but some recent studies have suggested that sarcosine exhibits 67 
considerable stimulatory effects on growth in malignant/metastatic prostate cells [19], possibly 68 
due to accumulation in the tumor and consequential conversion to serine and glycine, thereby 69 
providing tumor growth promoters [20,21].  70 
Laboratory based techniques for sarcosine detection are typically high performance 71 
chromatography [22], whereas several different approaches have been suggested to provide a 72 
nearer-patient diagnostic.  For example, Biavardi et al., [23] designed a direct binding cavitand, 73 
anchored on a Si-substrate, that showed a change in the fluorescence in the presence of 74 
sarcosine, whereas Valenti et al., [24] used the same cavitand to provide selectivity in an 75 
electrochemiluminesce system. In contrast, others have proposed an immunoassay [25] which 76 
was able to discriminate sarcosine in urine samples with good sensitivity and without undesired 77 
interference in well controlled assay conditions, although quantification in a near-patient 78 
diagnostic measurement remains challenging. 79 
 80 
Currently available sarcosine test kits mainly use a classical oxidase linked assay, and although 81 
there are reports of amperometric sarcosine biosensors with sarcosine oxidase, using the same 82 
principle as first and second generation glucose oxidase biosensors [26], most of the test kits 83 
that are already available are colorimetric or fluorometic versions of this classical oxidase assay. 84 
These are based on an indirect measurement of sarcosine via the coproduct H2O2, catalysed by 85 
horseradish peroxidase and taking advantage of the myriad of dyes that can be coupled into this 86 
reaction as indicator. Nevertheless, although these types of kit are suitable for use in plasma and 87 
serum, interference in measurements made in urine is typically reported, producing erroneous 88 
results. Some attention has been given to overcoming this interference, for example Lan et al. 89 
used 3,3’,5,5’-tetramethylbenzidine with palladium nanoparticles as a catalyst instead of 90 
horseradish peroxidase [27] and Burton et al. directed their attention to the other coproduct 91 
(formaldehyde) and the pH change associated with its conversion to formic acid under 92 
optimised conditions [28]. However, these methods have required quite a lot of laboratory based 93 
processing in the analytical pathway; for example the latter method [28] requires the introduction 94 
of NaOH and heat, for the Cannizzaro reaction to proceed which converts the formaldehyde to formic 95 
acid and methanol and degrades the hydrogen peroxide. This isn’t suitable for development of a 96 
biosensor and thus, interference of the measurement in urine remains a challenge for a near 97 
patient diagnostic. 98 
 99 
Most of these assays use solution based reagents. However, it has been reported that 100 
immobilized enzymes can in some cases, exhibit higher selectivity and sensitivity [29], but on 101 
the other hand, chemical modification during immobilization can cause enzyme degradation or 102 
block the active centre, or result in the enzyme orientation being incorrect for reaction with the 103 
enzyme substrate. [30] Peptide molecular biology immobilization techniques can be inspired by 104 
high affinity peptides from binding patterns in nature [31] which allows an immobilisation 105 
functionality to be fused with the reagent enzyme (e.g. sarcosine oxidase) during protein 106 
expression. This allows attachment of the protein on a surface to be in-built without further 107 
chemical modification and may help to better retain enzyme activity. We have recently taken 108 
inspiration from “Garage Biotech” [32] and shown that an engineered sarcosine oxidase (SOx), 109 
immobilised on silica via a silaffin peptide tag [33] can retain exquisite selectivity for sarcosine.  110 
A simple one-step isolation-to-use method is presented which produces a silica particle-enzyme 111 
sensor. It is low cost, biocompatible and stable in most biosystems [34].  112 
 113 
We have therefore returned to the sarcosine oxidase linked assay and considered whether the 114 
assay can be optimised for measurement in urine by focusing on the presentation of the enzyme 115 
and other reagents, and thereby, develop a biosensor where all the reagents are immobilized on 116 
a solid support, leading to good point of care usability, rapid result outcome. Successful 117 
(bio)molecule immobilization has been demonstrated to be beneficial for diverse 118 
biotechnological and medicinal applications [35]. In the research reported herein, we use both 119 
chemical immobilisation techniques and protein engineering to improve long term protein 120 
stability and aid performance in the design of in vitro diagnostics (IVD). We used the novel 121 
enzyme-silica combination in order to study its compatibility in urine and to develop a 122 
fluorometric sensor for sarcosine detection in human urine, by incorporating all needed reagents 123 




2. Materials and methods 128 
 129 
2.1 Materials and reagents 130 
 131 
Enzymes used for cloning (restriction enzymes, calf intestinal alkaline phosphatase, Antarctic 132 
phosphatase, T4 DNA ligase) and Quick Ligation kit were purchased from New England 133 
Biolabs and were used according to the manufacturer's instructions. Plasmid pET24a (Novagen) 134 
containing the R52-mCherry-mSOx-R5-6H gene was produced previously in the Hall 135 
laboratory, Cambridge. Details have been reported previously [33].  136 
 137 
The enzyme sarcosine oxidase from Bacillus sp. (25-50 units/mg), peroxidase from horseradish 138 
(50-150 units/mg), lysozyme from chicken egg white lyophilized powder and the analyte 139 
sarcosine were purchased from Sigma Aldrich (Saint Louis, USA). The particles used were 140 
glass bubbles microspheres/microballoons from easycomposites (Stoke-on-Trent, UK), gel 141 
silica particles <63 µm from Fluka (Monte Carlo, Monaco), TLC-Kieselgel 60H average 142 
particle size 15 µm (90% between 3.5 – 25µm) from Merck (Darmstadt, Germany) and 143 
microparticles from YMC (Hong Kong, China) (range 63-210µm) and glass beads unwashed 144 
(450-600 µm) were from Sigma Aldrich (Saint Louis, USA). The silica particles were modified 145 
with tetraethyl orthosilicate, 3-(aminopropyl)triethoxysilane ammonium hydroxide solution (28-146 
30%)  from Sigma Aldrich (Saint Louis, USA). The fluorescent probe Amplex Red was 147 
obtained from Sigma Aldrich and the sensitive Amplex UltraRed was provided by Invitrogen, 148 
ThermoFisher Scientific.  149 
 150 
The artificial urine was prepared using urea, creatinine, sodium chloride, sodium bicarbonate, 151 
calcium chloride, sodium phosphate monobasic, citric acid provide from Sigma Aldrich (Saint 152 
Louis, USA) and ammonium sulphate and sodium sulphate obtained from Fischer Scientific 153 
(Waltham, USA). Arginine, tryptophan, serine, glycine leucine and uric acid were used to test 154 
the selectivity of the assay and were purchased from Sigma Aldrich (Saint Louis, USA). Urine 155 
samples were provided by the La Fe Hospital and Clínico Hospital of Valencia, Spain. Dark 96-156 
well plates and clear 96-well plates used for fluorescence and absorbance measurements 157 
respectively, were provided by Thermo Scientific (Roskilde, Denmark).  158 
 159 
2.2 Instruments 160 
 161 
A Varian Cary Fluorescence Spectrophotometer from Agilent (Santa Clara, USA) was used for 162 
fluorescence measurements and a spectrophotometer synergy HT from Biotek Intruments Ltd 163 
(Winooski, USA) was used for absorbance measurements. Characterization of particles by 164 
FTIR-ATR was carried out with a Cary 630 FTIR-ATR spectrophotometer Agilent Technologies 165 
(Böblingen, Germany). A Nikon EFD-3 microscope was used for the optical and fluorescence 166 
images.  167 
 168 
The incubator used for the synthesis of the fusion protein was the Innova 4300 incubator shaker 169 
from New Brunswick Scientific (Enfiel, USA). The centrifuge used was megafuge 1OR for 170 
larger volume (flacon tubes) and Biofuge pico for small volume (eppendorf) both form Heraeus 171 
Intruments (Hanau, Germany). The pH values were determined with pH meter 3510 from 172 
Jenway (Staffordshire, UK) calibrated at room temperature with standard buffers.  173 
 174 
2.3 Expression and isolation of the protein 175 
 176 
Protein design, expression and isolation has been described previously [33].  The constructs 177 
were designed with a coloured fluorescent protein (mCherry, mCh) to enable easy monitoring of 178 
production, and a silaffin peptide sequence for immobilisation to silica.  The plasmid was 179 
designed previously and provided for this project. Before expressing the protein, BL21(DE3) E. 180 
coli containing the desired plasmid were grown overnight in a starter culture of 20 ml Luria 181 
Broth (LB). Then, 200 µL from overnight culture was transferred to 20 mL of LB Broth with 182 
kanamycin (10 µL, 100 mg/mL) and the solution was left overnight in the 37ºC shaking 183 
incubator. The culture was transferred to 200 mL LB Broth with kanamycin (100 µL, 100 184 
mg/mL) and it was incubated for 3 h in the shaking incubator. Then, isopropyl-b-D-1-185 
thiogalactopyranoside (IPTG) was added as initiator and it was incubated for 4-5 h during 186 
protein expression. Due to the internally fused mCherry label, production could be followed by 187 
the development of the pink colour. The culture was centrifuged at 4300 rpm for 20 min at 4ºC. 188 
The supernatant was discarded and the pellet was stored at 4ºC. The protein was obtained from 189 
the cell by lysing with lysozyme (10 mg/mL), sonication for 30 s on /30 s off for 3 cycles; 20 s 190 
on / 30 s off  for 5 cycles; 10 s / on 10 s off for 10 cycles. The mixture was centrifuged at 13000 191 
rpm for 20 min at 4ºC, the supernatant which contained the impure protein was stored at 4ºC.  192 
 193 
2.4 Immobilization on silica particles 194 
 195 
The immobilization of R52-mCherry-mSOx-R5-6H on silica particles followed the procedure 196 
reported previously [33] with some modifications. The modified protocol was carried out using 197 
a suspension of silica particles (10 mg/mL, 5 mg in 0.5 mL), prepared in disodium phosphate 198 
buffered saline (100 mM phosphate, 150 mM NaCl, pH 7.5). The mixture was sonicated for 1 h 199 
and then 150 µL of crude protein (0.8 mg/mL) was added. The final concentration of the protein 200 
was 0.18 mg/mL. After mixing it by vortex, the suspension was left for 1 h at room temperature 201 
to precipitate. The particles became pink and the supernatant colourless. Finally, it was 202 
centrifuged at 13000 rpm for 5 min. The final protein loading for SiO2-R52-mCherry-mSOx-R5-203 
6H was 24µg protein/mg silica. 204 
 205 
The selectivity of R52-mCherry-mSOx-R5-6H for silica against other materials such as alumina, 206 
titanium oxide, calcium carbonate, cellulose and chitosan and were tested following the same 207 
protocol. Also, the protocol was followed to test the immobilization of R52-mCherry-mSOx-R5-208 
6H for different particle size of silica. 209 
 210 
To test the R52-mCherry-mSOx-R5-6H loading on silica, different concentration of crude 211 
protein (0.8mg/mL) or pure protein (4mg/mL) were added to 5 mg of silica in 0.5 mL of 212 
disodium phosphate buffer saline (100mM phosphate, 150 mM NaCl pH: 7.4) separately and 213 
the protocol was followed.  214 
 215 
To evaluate the R52-mCherry-mSOx-R5-6H resistance to leaching: the particles were washed 216 
several times with water and buffer and no leaching of the protein from the particles to the 217 
solution was observed.  The R5-protein could be partially released in acidic media (pH 4), after 218 
30 min (around 40% of release) while higher release (85%) could be achieved using lysine 219 
solution 1M, pH 7.4. 220 
 221 
For the chemical immobilization of commercially available SOx and HRP, the protocol 222 
followed was developed previously by the Cambridge Analytical Biotechnology group for 223 
protein labelling of silica nanoparticles reported by [36,37]. The modified protocol described 224 
here, the NH2-modified silica particles were obtained by mixing TEOS (0.6 mL) in an ammonia 225 
solution (30 % wt, 0.5 mL) and 0.1 g of silica particles. The mixture was stirred for 1 h. then, 226 
APTES (0.2 mL) was added and the mixture was agitated for 4-5 h at room temperature. After 227 
the reaction was completed, the particles were centrifuged, washed several times with water and 228 
ethanol and were dried overnight. Finally, a glutaraldehyde (GA) aqueous solution (1.6 % wt 229 
GA, 1 mL) was added to the obtained GA modified silica particles and the reaction was stirred 230 
for 3 h at room temperature. The particles changed from white to yellow and then, orange. The 231 
GA-silica particles were centrifuged, washed several times with water. Finally, they were 232 
dispersed in a solution of HRP (2 mg/mL, 1mL giving 0.04 HRP/2mg particles) or SOx (1.5 233 
mg/mL) and stirred for 4-5 hours at room temperature. The HRP-SiO2Ps and SOx-SiO2Ps were 234 
centrifuged and washed three-four times with water and dried overnight.  235 
 236 
Amplex Ultrared was immobilized by mixing TEOS (0.6 mL) in an ammonia solution (30 % 237 
wt, 0.5 mL) and 0.1g of silica particles with stirring for 1 h. 20 µL of stock solution of Amplex 238 
Ultrared in DMSO (10 mg/mL) was then added and stirred for 30 minutes. Finally, the 239 
supernatant was removed by decantation and the particles were dried at room temperature in the 240 
dark for 4 h. The colour of the particles changed from white to pink. The same experimental 241 
process was used for the immobilization of Amplex Red.  242 
 243 
2.5 Estimation of immobilized protein on silica particles 244 
 245 
Protein loading was checked by comparing data from two methods. Taking advantage of the 246 
fluorescence of the fused internal mCherry reference, direct estimation of immobilized protein 247 
is possible. The percentage of immobilized protein was calculated by the difference of 248 
fluorescence intensity (lex/em 587 / 607 nm) of the free protein in the supernatant at the 249 
beginning (I sol)  and end  (I sup) of the immobilisation, in equation (eq.) 1 : 250 
 251 
%	𝑜𝑓	𝑖𝑚𝑚𝑜𝑏𝑖𝑙𝑖𝑧𝑒𝑑	𝑝𝑟𝑜𝑡𝑒𝑖𝑛	𝑜𝑛	𝑠𝑖𝑙𝑖𝑐𝑎	 = 100 −	789:;	<	89=>
89:;	
· 	100@                (eq. 1)             252 
 253 
The Bradford assay [38] for the estimation of protein concentration using Coomassie brilliant 254 
blue and bovine serum albumin as a standard was employed.  255 
 256 
2.6 Estimation of the enzyme activity 257 
 258 
Trinder’s colorimetric assay was adapted for sarcosine oxidase and used to measure the activity 259 
of R52-mCherry-mSOx-R5-6H in solution and immobilised on SiO2 particles compared with 260 
commercial sarcosine oxidase. The assay was carried out in disodium phosphate buffer (150-261 
300 µL, 10 mM, pH 7.5) with 4-aminoantipyrine (50 µL, 1% w/v), phenol (50 µL, 1% w/v), 262 
sarcosine (50 µL, 2 M), HRP (50 µL, 0.4 mg/mL) and the R52-mCherry-SOx-R5-6H (10 µL, 4 263 
mg/mL) or SiO2-R52-mCherry-SOx-R5-6H (2.5 mg, 4 mg/mL) or commercial sarcosine oxidase 264 
(10 µL, 2.4 mg/mL). After 5 min, 2.5 mL of ethanol was added to stop the reaction and the 265 
absorbance was registered at 480 nm. Total protein was measured by Bradford assay [42]. 266 
Specific activity was estimated by calculating the Units of enzyme activity per mg of total 267 
protein measured. 268 
 269 
A similar protocol was used to measure the activity of HPR and HRP-SiO2 particles. A solution 270 
of disodium phosphate buffer (300 µL, 10 mM, pH 7.5) with 4-aminoantipyrine (50 µL, 1% 271 
w/v), phenol (50 µL, 1% w/v), H2O2 (50 µl, 2M) and the HRP (10 µL, 0.4 mg/mL) or 2 mg of 272 
HRP-SiO2Ps (containing 40µg protein). After 5 min, 2.5 mL of ethanol was added to stop the 273 
reaction and the absorbance was registered at 480 nm. 274 
 275 
2.7 Sarcosine measurements 276 
 277 
Preparation of artificial urine. Minimal artificial urine has been constituted for different 278 
purposes [39]. In this case artificial urine was constituted based on the Brooks and Keevil 279 
recipe, adjusted to be protein-free at pH = 6.2 and comprising of urea (170 mM), ammonium 280 
sulphate (12.5 mM), sodium chloride (90 mM), sodium bicarbonate (25 mM), sodium sulfate 281 
(10 mM), creatinine (5.30 mM), calcium chloride (2.5 mM) sodium phosphate monobasic 282 
anhydrous (7 mM), citric acid (2 mM). The solution was stored in the refrigerator (4 ºC) until 283 
use. 284 
 285 
Determination of sarcosine using the reagents in solution. The determination of the sarcosine 286 
was based an enzyme linked assay using sarcosine oxidase and the indirect detection of H2O2, 287 
using Amplex Ultrared (AR) and horseradish peroxidase (HRP) as a catalyst (See Fig. 1B). 288 
Different volumes of sarcosine solution (0-10 µL, 100 µM) were added to 70 µL artificial urine 289 
or urine, followed by 10 µL of HRP 0.4 mg/mL and 10 µL of SOx 1.2 mg/mL and 10 µL of AR 290 
(100 µM) to a final volume of 100 µL. After reaction for 20 min at room temperature in the 291 
dark, the fluorescence was measured (lex/em 530 / 582 nm). The increment of fluorescence 292 
intensity of sarcosine standard (ISar) with respect to the blank (I0) was plotted against the 293 
concentration of sarcosine and expressed as follows: Istand - I0 = a + b [Sarcosine]  294 
 295 
Determination of sarcosine using the immobilized reagents on silica particles. Different 296 
volumes of sarcosine solution (0-10 µL, 100 µM) were added to a final volume of 100 µL of 297 
artificial urine containing 5 mg of protein-SiO2 particles, 2 mg of HRP-SiO2 particles and 5 mg 298 
of AR-SiO2 particles. After reaction for 20 min at room temperature in the dark, the 299 
fluorescence was measured (lex/em 530 / 582 nm) as above.  The same experimental process was 300 
followed in urine to obtain the calibration curve for sarcosine standards in control urine. 301 
 302 
Well-cards were produced a 5mm diameter wells, cut from 1mm PMMA and sealed on one side 303 
with PCR plate seal (Thermo Scientific Adhesive PCR Plate Seal). 4 µL each of HRP (0.4 304 
mg/mL), sarcosine (0-5µM final concentration) and AR (10µM) were added to 125µg silica-305 
R52-mCherry-mSOx-R5-6H suspended in artificial urine (20µL total assay volume). 306 
Fluorescence intensity was recorded with an FFEI reader (505nm LED for excitation and a 307 
CCD RGB linear sensor for detection). Rate of change of average intensity in the well was 308 
plotted against final concentration of sarcosine, blank subtracted. 309 
 310 
The design and construction of the hourglass sensors has been described in detail elsewhere [33] 311 
for the protein modified silica.  They were produced by laser cutting the hourglass shape from 312 
2mm PMMA and sealing both sides with PCR plate seal (Thermo Scientific Adhesive PCR 313 
Plate Seal). A suspension (total 220µL) of the R52-mCherry-mSOx-R5 immobilized on silica (1 314 
mg silica, 0.025 mg/mL protein per 1mg silica) was mixed with AR (10µL, 100µM), HRP 315 
(10µL, 0.4mg/mL) and sarcosine (final concentrations 0µM - 11.75µM)) in artificial urine 316 
/urine was loaded into the device.  The device was inverted twice for mixing, each time 317 
allowing the particles to settle to the bottom (60s). Fluorescence intensity was recorded with an 318 
FFEI reader (505nm LED for excitation and a CCD RGB linear sensor for detection) every 319 
minute for 18min. The images were analysed for grey scale intensity of the red channel in the 320 
detection area using ImageJ software. 321 
 322 
Preliminary analysis of urine samples. Samples from 5 healthy volunteers and 10 cancer 323 
patients were provided from Hospital la Fe and the Clinic Hospital, Valencia, Spain and were 324 
stored at -20ºC until testing. The samples were brought to room temperature for 10 min and 325 
used for the assay without treatment or dilution. For the assay, 100 µL of urine containing 5 mg 326 
of protein-SiO2 particles (containing <120µg protein), 2 mg of HRP-SiO2 particles (containing 327 
<40µg protein) and 5 mg of AR-SiO2 particles. After reaction for 20 min at room temperature in 328 
the dark, the fluorescence was measured at (lex/em 530 / 582 nm). The increment of fluorescence 329 
intensity of sarcosine standard (ISar) with respect to the blank; real urine with a sarcosine content 330 
below LOD, (I0), for each sample was interpolated on the calibration curve of sarcosine 331 
standards in urine in order to obtain concentration of sarcosine.  332 
 333 
2.8 Selectivity and stability 334 
 335 
For the selectivity, stock solutions of amino acids such as alanine, arginine, glycine, leucine, 336 
serine and tryptophan and uric acid were prepared at concentration of 1 mM. The solutions were 337 
diluted in artificial urine to final concentrations of 10 µM. A mixture of all of them with 338 
sarcosine were prepared to final concentrations of 10 µM. In addition, a sarcosine standard of 339 
10 µM in artificial urine (ISar) and a blank (I0) was used as a reference. Then, 5 mg of protein-340 
SiO2Ps, 2 mg of HRP-SiO2Ps and 5 mg of AR-SiO2Ps were added to 100 µL of each diluted 341 
solutions (Ii) and after reaction for 20 min at room temperature in the dark, the fluorescence was 342 
measured at excitation/ emission wavelength 530 / 582 nm. The relative fluorescence was 343 




· 	100                    (eq. 2) 346 
 347 
For the stability of the mSOx, a solution of commercial SOx (2.4 mg/mL) was stored for 90 348 
days at room temperature. The obtained R52-mCherry-SOx-R5-6H and the immobilized protein 349 
on silica were also stored at room temperature for 90 days. A fresh solution of commercial SOx 350 
at 2.4 mg/mL prepared before the analysis as well as just expressed protein and immobilized on 351 
silica were used as a reference. A volume of 10 µL of fresh (Ii 0 day) and stored solutions (Ii 90 days) 352 
of the commercial SOx, R52-mCherry-SOx-R5-6H or 5 mg of SiO2-R52-mCherry-SOx-R5-6H 353 
were dispersed in artificial urine. Then, 10 µL of sarcosine standard (100 µM) or 10 µL of water 354 
for the blank (I0), 10 µL of HRP 0.4 mg/mL and 10 µL Amplex Ultrared were added. The final 355 
volume of each one was 100 µL. After reaction for 20 min at room temperature in dark, the 356 
fluorescence was measured at excitation/ emission wavelength 530 / 582 nm. The relative 357 





· 	100        (eq. 3) 360 
 361 
For the stability of the fluorescence of mCherry-6H and R5-mCherry-6H on thin-layer 362 
chromatography (TLC) was measured by deposition of 1µL of each  (1mg/mL) on silica TLC 363 
plates using glass capillaries. Then, the plates were left at room temperature for 1 month. 364 
Images of the spot were taken under the fluorescence microscope and fluorescence scans were 365 
performed with an FFEI reader (505nm LED for excitation and a CCD RGB linear sensor for 366 
detection) at various time points. Fluorescence intensity in the red channel of the scans was 367 




3. Results and discussion 372 
 373 
3.1 Components for a silica-SOx biosensor platform.  374 
 375 
Sarcosine oxidase belongs to the same family of enzymes as the ubiquitous glucose oxidase, so 376 
that in considering an approach to sarcosine measurement in urine, many lessons can be learned 377 
from the long history of glucose oxidase biosensors.  However, in comparison with the two 378 
electron oxidation mechanism involving glucose oxidase [40], which has a specific activity 379 
ranging from 172-300 U/mg (µmol/min/mg), the specific activity for the one electron process 380 
with sarcosine oxidase is more than an order of magnitude lower.  This poses significantly 381 
greater challenges in localizing sufficient enzyme in the vicinity of a transducer to generate a 382 
measurable signal for a biosensor and retaining sufficient activity in the immobilisation process. 383 
Using the classical glutaraldehyde coupling method for protein crosslinking, the specific 384 
activity of sarcosine oxidase (SOx) is reduced from ~9U/mg to ~0.09U/mg.  This can be 385 
improved by chemical coupling with an NH2 activated surface on silica particles, but the 386 
residual activity remains too low (~0.4U/mg, table 1) for use in a biosensor.  In this work 387 
therefore, we consider self-immobilization directly from the protein without chemical coupling, 388 
by using synthetic biology to design a multicomponent fused protein. The philosophy of this 389 
approach is to include capacity for selective immobilization in the original enzyme design, by 390 
fusing an affinity peptide to the enzyme prior to expression.  391 
 392 
Many affinity peptides have been identified for different materials [31] and in this example we 393 
have considered the use of silica as the core material platform for enzyme presentation.  We 394 
have previously expressed a novel fusion protein: (R5)2-mCherry-sarcosine oxidase-R5-6H 395 
(R52-mCherry-SOx-R5-6H) [33]. The R5 peptide described here is a 19 amino acid peptide 396 
(NH2-SSKKSGSYSGSKGSKLLIL-COOH). It is derived from diatoms [41, 42] and enables the 397 
protein to “self-immobilise” by adsorption on silica particles (See Fig. 1). It has previously been 398 
reported in protein encapsulation with silica [43] or to enhance precipitation of the protein 399 
through silica encapsulation [44].  In contrast, we do not seek encapsulation, but have selected 400 
this peptide as an affinity tag for immobilisation on silica substrates. Leading on from 401 
preliminary results [33], the application of this silica-immobilised sarcosine oxidase is now 402 
explored in determination of sarcosine together with HRP and Amplex Red as silica bound 403 
reagents for a solid state measurement in urine, without the interference that is typical when this 404 
assay is deployed in this sample matrix.  405 
 406 
 407 
Fig. 1. Scheme of the biosensor platform for the assay of sarcosine determination in urine. (R5)2-408 
mCherry-Sarcosine oxidase-R5-6H, the catalyst horseradish peroxidase (HRP) and the fluorophore 409 
Amplex Ultrared (AR, pink surface on silica particle) were immobilized on silica particles. The sarcosine 410 
oxidase generates H2O2 in the presence of sarcosine which in turn results in the conversion of AR to a 411 
fluorescent product by HRP. 412 
 413 
A fluorometric assay for sarcosine has been proposed based on the pathway reported in Fig.1. 414 
Central to the design of this system is the role of the R5 peptide on protein immobilization on 415 
silica. The experimental process of R5-protein immobilization is an easy, fast method where no 416 
additional coupling reagents are needed, other than the protein and the silica substrate in buffer. 417 
The mechanism of protein immobilization on silica involves electrostatic interaction with 418 
release of water at physiological pH, driven by the silanol/siloxide groups on the silica surface 419 
and positively charged residues on the R5 polypeptide [45, 46]. The efficiency of target R5 in 420 
enzyme immobilization on silica particles (Section 2.5, eq.1) was studied comparing the amount 421 
of protein immobilized for R52-mCherry-SOx-R5-6H with native SOx and mCherry. The 422 
immobilization of R52-mCherry-SOx-R5-6H on silica particles resulted in approximately 99% 423 
efficiency based on the inbuilt mCherry fluorescence lex/em = 587 / 607 nm of supernatant 424 
solution (Section 2.5, eq. 1) as can be seen in Fig. 2A and very selective to silica as a substrate 425 
(Fig. 2B). For solutions of purified R52-mCherry-SOx-R5-6H enzyme, loading on silica was 426 
proportional to the enzyme concentration in the incubation solution (Fig. 2C) with 427 
immobilisation efficiency independent of enzyme concentration (Fig. S1A). 428 
   429 
Whole Urine 
AR 
In the absence of R5, only ~50% of SOx could be adsorbed non-specifically compared with 430 
~99% R5-SOx. A higher level of adsorption was found with mCherry-6H (~80% ) without the 431 
R5 (See Fig. 2A) but with loss of fluorescence (Fig. 2D). Red fluorescent proteins have been 432 
seen to have a susceptibility to loss of fluorescence, due to loss of secondary structure and 433 
denaturing on silica [47]. When mCherry-6H and R5-mCherry-6H are adsorbed onto a silica 434 
thin layer chromatography plate, Fig. 2D, mCherry-6H is adsorbed but the fluorescence is lost 435 
rapidly at room temperature for the native enzyme. In contrast, R5-mCherry-6H retained full 436 
fluorescence activity over 24 hrs, decaying only slowly and still retaining >60% of the original 437 
activity after one month (See Section 2.8). The R5-tagged mSOx is also resistant to leaching at 438 
normal physiological pH and even at alkaline pH. It could be partially released in acidic media 439 
(pH 4) after 30 min (around 40% of release). In addition, lysine (Lys) at high concentrations is 440 
able to competitively displace the R5 from the silica [48]. It can be seen in Fig. 2E that 85% of 441 
R52-mCherry-SOx-R5-6H was released using lysine at 1M pH 7.4, however these conditions 442 
are not representative of urine. In urine, loss of R52-mCherry-SOx-R5-6H from the silica was 443 
less than 4%. 444 
 445 
 446 
 Fig. 2. A) Protein immobilisation on silica dependent on the presence or absence of the R5 silaffin 447 
polypeptide component for mCherry and SOx constructs (immobilisation from a solution of 0.4 mg/mL 448 
protein), B) selectivity of R52-mCherry-mSOx-R5-6H for silica compared with other substrates C) R52-449 
mCherry-mSOx-R5-6H loading on silica depending of its concentration in the immobilisation incubation, 450 





























































































































































chromatography (TLC) plate and the relative red channel fluorescence intensity (%) measured using an 452 
FFEI reader and analysed with ImageJ; E) R52-mCherry-mSOx-R5-6H leaching under strong conditions 453 
lysine 1M, compared with different pH; F) Stability of commercial wildtype SOx, R52-mCherry-mSOx-454 
R5-6H  in solution and the SiO2- R52-mCherry-mSOx-R5-6H  at room temperature for 90 days. 455 
 456 
The silica used for the immobilization of the reagents can be obtained from natural resources 457 
such sand and from rice (Fig. S6) or purchased as narrow or broad range sized particles. 458 
Immobilisation efficiency (eq. 1) is influenced by silica particle size, and a decrease in 459 
immobilisation efficiency can be observed for larger particles. The best results were obtained 460 
for silica particles between 0.25 to 60 µm using concentrations of the protein between 0.2-0.4 461 
mg/L (See Fig. S1B). This is also consistent with other work using the Car9 silica affinity 462 
peptide [49]. Silica of sand origin or silica particles of 60 µm were selected due to their easy 463 
precipitation with the protein, during the protein immobilization process, without need of 464 
centrifugation.  465 
 466 
The effect of immobilisation on the enzyme activities was also highlighted for the wildtype SOx 467 
and R52-mCherry-mSOx-R5-6H, measured using the Trinder assay (See Section 2.6). Table 1 468 
compares the specific activity for mSOx in solution and immobilised on silica using either the 469 
traditional chemical method of crosslinking with glutaraldehyde to an amino activated silica 470 
(see Section 2.4) or via the R5 affinity peptide. Although the solution of crude lysate containing 471 
R52-mCherry-mSOx-R5-6H had a relatively low specific activity of 1.33 U/mg, after selective 472 
immobilisation on to silica of the R52-mCherry-mSOx-R5-6H from the crude extract, this 473 
increases to 5U/mg, compared with 7.49 U/mg for the isolated purified protein.  For 474 
comparison, the GA-linked SOx drops to 0.4 U/mg protein on silica, compared with 9.6 U/mg 475 
in solution. 476 
 477 























9.6±0.5 0.09±0.03 0.4±0.2 1.33±0.13  7.49±0.08 5  ±  0.3 323 ± 5 21 ± 1 
 479 
The stability of the free and silica immobilised proteins showed clear differences when studied 480 
at room temperature over time (60 and 90 days) (Fig. 2). It is clear from this figure that the R5-481 
mCherry fusions have produced a more robust protein with almost no loss of activity in 90 days, 482 
whereas the proteins without R5 lose more than 90% of their relative activity. The data for this 483 
robust R52-mCherry-SOx-R5-6H provides a good basis for development of a sarcosine 484 
biosensor. 485 
 486 
3.2 Towards a sarcosine biosensor using SiO2-R52-mCherry-mSOx-R5-6H 487 
The enzyme-SiO2 particle system allows different assay configurations to be considered. The 488 
SiO2-R52-mCherry-mSOx-R5-6H enzyme is very suitable for a packed column/bed format. Fig. 489 
S5 shows the microfluidic system developed recently for an immunoassay biosensor [36], 490 
repurposed here for an enzyme assay. In contrast as reported recently elsewhere [33], utilising 491 
the principles of an hour glass and silica obtained from sand (Fig S6), Fig. S7 shows a thin film 492 
hour-glass cell containing R52-mCherry-mSOx-R5-6H protein on silica. This was filled with 493 
artificial urine and then inverted to cause the silica to fall through the sample and precipitate at 494 
the base. Fig. S6 shows that by obtaining the change in the fluorescent intensity profile through 495 
the cell for a given time interval (6 min was selected) a linear relationship with sarcosine 496 
concentration is revealed.  More conventionally Fig. 3A shows the calibration curve for 497 
sarcosine with SiO2-R52-mCherry-mSOx-R5-6H particles in artificial urine a simple eppendorf. 498 
As can be seen from the plot, there is good linearity across the range of potential clinical interest 499 
for identifying elevated sarcosine levels (>5µM) in patients with prostate cancer.  500 
 501 
However. the assay can also be formulated to work as a spot test with very low volume samples 502 
(eg 20µL, Fig. 3B) with a fluorescence output that can be read visually against an intensity 503 
match card (see Fig. 3B) to provide a simple positive/negative result.  A quantitative 504 
measurement can also be obtained in this format with resolution adjusted for either high or low 505 
sarcosine levels.  For example, as can be seen in the plot in Fig. 3B, the reader intensity is set to 506 
give a maximum at 3.5 µM (in the normal clinical range) so that measurement reaches signal 507 
saturation at higher concentrations.  508 
 509 
These preliminary results using artificial urine show promise for further construction of the 510 
SiO2-R52-mCherry-mSOx-R5-6H biosensor. However, this requires the coimmobilisation of the 511 
HRP and Amplex Red. 512 
 513 
3.3 Addition of HRP-SiO2 514 
 515 
The stoichiometric coproduct from the SOx catalysed oxidation of sarcosine is H2O2 which acts 516 
as an indirect measurand of sarcosine, producing a colorimetric product catalysed by HRP (Fig. 517 
1B). However, although horseradish peroxidase (HRP) is widely used in such combinations, 518 
recombinant HRP is difficult to express and has a tendency to form inclusion bodies (IBs) in 519 
E.coli with low yield [50] of active protein.  Thus, commercially available peroxidases are 520 
largely from plant extracts and are a mixture of acidic and basic isoenzymes. We have 521 
previously shown that some engineered type C R5-HRP isoenzymes, expressed in E.coli can be 522 
produced without IBs, but this isoenzyme has an activity of ~0.2U/mg compared with 523 
>300U/mg for the commercial mixed isoenzyme HRP of plant origin. In this instance, the wild 524 
type mixed acidic and basic HRP isoenzyme with high initial activity, is thus the preferred 525 
enzyme source for a first step in a peroxide linked sarcosine assay. This required a classical 526 
chemical immobilisation of HRP using GA coupling. This does not share the same benefits as 527 
the easy R5 protein modification, of being coupling-reagent free and single step, but provides a 528 
compatible stepwise model for taking the silica platform forward to explore whether sarcosine 529 
can be detected in urine. 530 
 531 
In the HRP-silica containing samples, the FTIR (Fig. S2A) is dominated by a band at 1089 cm−1 532 
which corresponds to Si-O-Si antisymmetric stretching vibrations. The presence of HRP is 533 
indicated by the characteristic absorptions at 1640 and 1540 cm−1, attributed to -CONH- (amide 534 
I) and amide II, respectively (see insert in Fig. S2A). The HRP-SiO2 particles are green and red 535 
autofluorescent (Fig. S2B) similar to observations in previous reports after glutaraldehyde 536 
crosslinking of serum albumins [51]. These authors attributed this observation to p–p* 537 
transitions of the C=O bond and n–p* transition of C=N bond as a result of the a,b unsaturated 538 
aldehyde. 539 
 540 
The activity of HRP-SiO2 particles (Section 2.6) compared with the free enzyme, showed the 541 
expected loss of activity following glutaraldehyde crosslinking (21±1 U/mg) (See Table 1) 542 
which is consistent with other reports of reduced activity following glutaraldehyde crosslinking 543 
[52] but nevertheless retains HRP activity at a higher level than the SOx, so that it should not 544 
limit the assay pathway. The SiO2-R52-mCherry-SOx-R5-6H and HRP-SiO2 can thus be 545 
combined for the determination of sarcosine and tested in artificial urine. As can be seen in Fig. 546 
3C, the behaviour observed for the free HRP and HRP-SiO2 in combination with SiO2-R52-547 
mCherry-SOx-R5-6H was broadly equivalent.  This provides a good basis for a fully 548 
immobilised SiO2-enzyme system. 549 
 550 
3.4 Addition of Amplex UltraRed-SiO2 551 
 552 
The silica particulate format offers versatility for the assay, so to complete the presentation on 553 
silica, the Amplex Red group of dyes were encapsulated on the surface of silica particles within 554 
a sol-gel using TEOS in basic conditions. The dye-SiO2 provided a vehicle for quick release and 555 
delivery of the reagent in contact with aqueous solution where the determination of sarcosine 556 
takes place. Under optimised conditions, with HRP-SiO2 and dye-SiO2 in sarcosine-spiked real 557 
urine, the results showed that Amplex Ultrared (AR) has around 2-fold higher sensitivity than 558 




Fig. 3. Calibration curves for sarcosine determination in artificial urine using R52-mCherry-SOx-R5-6H-563 
SiO2 together with A), HRP and AR (100µL sample in eppendorfs); B) HRP and AR in a well-card 564 
showing a quantitative plot of fluorescence intensity. Visual fluorescent intensity image of well-card for 565 
20µL samples shown with qualitative intensity image scale; C) AR and comparing the results with HRP 566 
and HRP-SiO2; D) HRP-SiO2 and comparing the sensitivity of Amplex Ultrared, AR (in black) against 567 
Amplex Red (in white) immobilized on silica E) HRP-SiO2 and AR-SiO2 compared with F) the 568 
commercial reagents SOx, HRP and AR in solution (note the different y axis scales). E and F tested in 569 
artificial urine and real urine from a control volunteer. Relative fluorescence measured at lex/em 530 / 582 570 
experimental details in Section 2.7 571 
 572 
3.5 Integrated sarcosine assay in urine 573 
The pH of normal urine is within the range of 5.5 to 7 with an average of 6.2 [54] while urine 574 
from cancer patients can be more acidic (pH 5). Amplex Ultrared has a broader useful pH range 575 
from pH5 to 8 compared with Amplex Red from pH 6 to 7 (See Fig. S3B). This shows that the 576 
pH should not affect the Amplex Ultrared for sarcosine determination in samples from either 577 
negative controls or positive patients. 578 
 579 
As mentioned earlier, the normal sarcosine test kit employing SOx suffers from interference for 580 
measurements in urine, producing artificially low results (assay kits warn against use in urine, 581 
but favour measurement in blood or serum, where sarcosine levels are not indicative for 582 
prostatic carcinoma).  This problem is also demonstrated here (Fig. 3F) using the commercially 583 
available reagents in solution, where the urine sample, spiked with sarcosine produces a very 584 
low fluorescence at 582nm, that is hardly sensitive to sarcosine concentration and only 4% of 585 
the slope for artificial urine.  This suggests that there is an inhibitor of the SOx or other matrix 586 
effect for the reaction in the real urine. In contrast, the fluorescence intensity of the solutions at 587 
582 nm for the silica-bound reagents showed a good linear relationship with sarcosine 588 
concentration between 0 to 10 µM, with a slope in urine that is 63 % of that obtained in artificial 589 
urine. It is evident that the silica-immobilised enzyme construct with SOx is less affected by the 590 
urine. By calibration in spiked screened urine from a healthy patient, the system adjusts for this 591 
background and provides excellent sensitivity in the required range, in contrast to the 592 
commercial SOx kit.  593 
 594 
It is known that the urinary amino acid alanine  which is at higher concentration than sarcosine 595 
in urine, is an interfering compound in sarcosine analysis by GC or LC coupled mass 596 
spectrometry, due to their equivalent parent and fragment [53-55]. On the other hand, glycine, 597 
which is a product of oxidative demethylation of sarcosine has also been shown to be a substrate 598 
for SOx with low activity.  Fig. S3A shows that alanine and glycine as well as some other 599 
amino acids produced only a small fluorescent signal in the absence of sarcosine, as does uric 600 
acid so that, alanine in particular, does not have the same significance as seen with coupled 601 
mass spectrometry detection.  Tyrosine and leucine appear to give a ‘negative’ signal, which 602 
can be correlated with the direct interaction with the Amplex dye, reducing the background 603 
fluorescence. Tyrosine dimerisation with H2O2 in the presence of HRP also forms a fluorescent 604 
product[56], which can influence the final signal, although this effect is typically small at this 605 
wavelength, since the emission is at a lower wavelength.  These matrix effects are independent 606 
of SOx concentration and can be accommodated in the background calibration with a combined 607 
effect reducing the overall signal by ~20% on silica, but still retaining the required resolution 608 
for sarcosine determination in clinical sample. In contrast, >80% reduction of the signal is 609 
observed with the wildtype SOx in solution and the sarcosine test kits. 610 
 611 
 612 
3.5 Application to urine from prostate cancer patients 613 
 614 
The validity of the sarcosine sensor to discriminate between samples from healthy volunteers 615 
and prostate cancer patients was tested. The samples were processed without any pre-treatment 616 
and without dilution avoiding sample contamination and reducing the time of the assay.  As 617 
mentioned before, the calibration slope obtained for artificial urine and urine was different, due 618 
to a matrix effect. In order to accommodate the matrix, the calibration curve was carried out in a 619 
real urine sample with a sarcosine content below the LOD. To evaluate the accuracy of the 620 
procedure, urine samples from cancer patients were also spiked with 5 and 10 µM of sarcosine. 621 
The recoveries obtained were near to 100% as can be seen in Fig. 4A suggesting that the 622 
calibration was robust. Three replicates were done in all the cases.  623 
 624 
Five samples from healthy volunteers or controls were compared with 10 samples of prostate 625 
cancer patients using the proposed ‘silica-enzyme’ biosensor. Higher intensities were found for 626 
prostate cancer patients compared with the control (See Fig S4). The concentrations of sarcosine 627 
calculated were 0 to 2.2 µM and 6.8 to 10.6 µM from healthy and patient samples, respectively. 628 
In Fig. 4B, the sarcosine concentration of cancer patients is shown to be about 4 times higher 629 
than for healthy donors. As a first approach, the sensor demonstrated here appears to be able to 630 
discriminate between healthy and prostate cancer patients.  631 
 632 
 633 
Fig. 4. A) The results obtained for a spiked sample from a patient with 5 and 10 µM of sarcosine 634 
(n=3). B) Comparison the mean concentrations of sarcosine estimated from urine samples of healthy 635 
volunteers (controls, n = 5) and PCa patients (patients, n = 10). For more experimental details see Section 636 

























4. Conclusions  641 
 642 
A novel fused protein R52-mCherry-Sarcosine oxidase-R5-6H was constructed which has the 643 
ability to self-immobilize on silica particles. The mCherry in the fused protein provided a useful 644 
visual reference throughout the production, isolation and immobilisation of the R52-mCherry-645 
SOx-R5-6H. This protein showed higher stability than the commercial SOx, and the protein 646 
remained stable for at least 3 months. In addition, it can be calibrated in and remains sensitive in 647 
complex matrices such as urine, while the classical SOx assay suffers from interferences and 648 
loses sensitivity. R52-mCherry-SOx-R5-6H, HRP and Amplex UltraRed were all successfully 649 
immobilized on silica particles to develop a particle based solid state sensor for sarcosine 650 
determination in urine. No sample preparation or treatment was needed and the reaction took 651 
place in urine at room temperature in 10-20 min. The proposed sensor is sensitive in the 652 
required clinical range for sarcosine detection in urine. Furthermore, in this preliminary study, it 653 
was able to discriminate between urine from healthy and prostate cancer patients.  654 
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